Lepu Biopharma

Lepu Biopharma, established in January 2018, is a biopharmaceutical company with a focus on oncology therapeutics. It was founded by Dr. Pu Zhongjie, who is also the founder of Lepu Medical. Dr. Pu has an extensive background in the medical field, holding bachelor's, master's, and doctoral degrees in metal materials and having served in various leadership roles at Lepu Medical since 1999. This experience in medical technology and materials science provides a strong foundation for leading a biopharmaceutical firm. The company's Chief Executive Officer, Dr. Sui Ziye, contributes nearly a decade of managerial experience in the pharmaceutical sector.

The company concentrates on developing treatments for unmet clinical needs in cancer, specifically in tumor immunotherapy and targeted therapies. Lepu Biopharma's business model is centered on the research and development, manufacturing, and commercialization of its drug pipeline. This is achieved through a combination of in-house R&D and strategic collaborations. A significant milestone was its initial public offering on the Hong Kong Stock Exchange on February 23, 2022, which raised approximately HK$876.3 million to fund the advancement of its clinical-stage products and expand its drug pipeline.

Lepu Biopharma has established an integrated platform that covers the entire biopharmaceutical value chain, from drug discovery and clinical development to GMP-compliant manufacturing and commercialization. The company's product pipeline includes antibody-drug conjugates (ADCs), immunotherapies, and oncolytic virus drugs. It has multiple drug candidates in various clinical trial stages, with some having entered registrational trials in China and one ongoing in the U.S. The company operates manufacturing facilities in Beijing and is expanding with new facilities in Shanghai to support its clinical trials and future commercial production. Revenue is generated from the sale of its pharmaceutical products, such as PUYOUHENG (Pucotenlimab Injection), which saw its revenue double in the first half of 2024 compared to the previous year.

Keywords: Lepu Biopharma, oncology therapeutics, biopharmaceutical, tumor immunotherapy, antibody-drug conjugates, ADC, clinical trials, cancer treatment, drug development, Pu Zhongjie, commercialization, GMP manufacturing, Pucotenlimab, Hong Kong Stock Exchange, oncology pipeline, targeted therapy, oncolytic virus, immuno-oncology, pharmaceutical R&D, cancer research